Top-News

Abivax Aktie News

Aktie
WKN:  A14UQC ISIN:  FR0012333284 US-Symbol:  AAVXF Branche:  Biotechnologie Land:  Frankreich
97,70 €
+2,90 €
+3,06%
21:55:51 Uhr
Depot/Watchlist
Marktkapitalisierung *
5,97 Mrd. €
Streubesitz
54,82%
KGV
-2,41
Index-Zuordnung
-

Abivax News

03.11.25 - EQS
EQS-News: Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Ulcerative Colitis
EQS-News: ABIVAX / Key word(s): Study results Abivax Announces Patient-​Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating ...
06.10.25 - EQS
EQS-News: Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies
EQS-News: ABIVAX / Key word(s): Conference/Study results Abivax Announces Late-​Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and ...
05.10.25 - EQS
EQS-News: Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data
EQS-News: ABIVAX / Key word(s): Conference/Study results Abivax Announces Late-​Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data 05.10.2025 / ...
29.09.25 - EQS
EQS-News: Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting
EQS-News: ABIVAX / Key word(s): Conference Abivax Announces Acceptance of Additional Late-​Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 ...
23.09.25 - EQS
EQS-News: Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting
EQS-News: ABIVAX / Key word(s): Conference Abivax Announces Presentation of Late-​Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United ...
12.09.25 - EQS
EQS-News: Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review
EQS-News: ABIVAX / Key word(s): Miscellaneous Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review 12.09.2025 / 17:45 CET/CEST The issuer ...
08.09.25 - EQS
EQS-News: Abivax Presents First Half 2025 Financial Results
EQS-News: ABIVAX / Key word(s): Half Year Results Abivax Presents First Half 2025 Financial Results 08.09.2025 / 22:00 CET/CEST The issuer is solely responsible for the content ...
08.09.25 - wallstreetONLINE Redaktion
Earnings Preview: Jetzt schlägt für Adobe, GameStop und SAP-Rivale Oracle die Stunde der Wahrheit!
Diese in den kommenden Tagen (KW37) anstehenden US-​Quartals­zahlen müssen Anlegerinnen und Anleger kennen: Herausforderungen, Erwartungen und die aktuell ...
07.09.25 - wallstreetONLINE Redaktion
Earnings Preview: Jetzt müssen sich Adobe, GameStop und SAP-Rivale Oracle ins Zeug legen!
Diese in den kommenden Tagen (KW37) anstehenden US-​Quartals­zahlen müssen Anlegerinnen und Anleger kennen: Herausforderungen, Erwartungen und die aktuell ...
01.09.25 - wallstreetONLINE Redaktion
Von 500 Mio. auf 6 Mrd.: Biotech-Rakete legt über 900 Prozent zu – Anleger reiben sich die Augen
Mitten im schwachen Biotech-​Jahr liefert Abivax das Kurswunder: Aktie und Marktwert verfielfachen sich, Hedgefonds feiern einen ihrer größten Coups 2025.Der französische ...
28.07.25 - EQS
EQS-News: Abivax Announces Closing of $747.5 Million Public Offering
EQS-News: ABIVAX / Key word(s): Capital Increase Abivax Announces Closing of $747.5 Million Public Offering 28.07.2025 / 22:15 CET/CEST The issuer is solely responsible for the ...
25.07.25 - EQS
EQS-News: Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)
EQS-News: ABIVAX / Key word(s): Capital Increase Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to ...
24.07.25 - EQS
EQS-News: Abivax announces trading resumption of its ordinary shares on Euronext Paris
EQS-News: ABIVAX / Key word(s): Miscellaneous Abivax announces trading resumption of its ordinary shares on Euronext Paris 24.07.2025 / 14:40 CET/CEST The issuer is solely ...
24.07.25 - EQS
EQS-News: Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares
EQS-News: ABIVAX / Key word(s): Capital Increase Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares 24.07.2025 / 14:40 CET/CEST The ...
24.07.25 - EQS
EQS-News: Abivax announces temporary trading halt of its ordinary shares on Euronext Paris
EQS-News: ABIVAX / Key word(s): Miscellaneous Abivax announces temporary trading halt of its ordinary shares on Euronext Paris 24.07.2025 / 07:30 CET/CEST The issuer is ...
23.07.25 - EQS
EQS-News: Abivax Announces Launch of Public Offering
EQS-News: ABIVAX / Key word(s): Financing Abivax Announces Launch of Public Offering 23.07.2025 / 22:15 CET/CEST The issuer is solely responsible for the content of this ...
22.07.25 - EQS
EQS-News: Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis
EQS-News: ABIVAX / Key word(s): Study results/Study Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-...
11.06.25 - EQS
EQS-News: Abivax Announces Results of its June 6, 2025 Annual General Meeting
EQS-News: ABIVAX / Key word(s): AGM/EGM Abivax Announces Results of its June 6, 2025 Annual General Meeting 11.06.2025 / 22:00 CET/CEST The issuer is solely responsible ...
02.06.25 - EQS
EQS-News: Abivax Presents First Quarter 2025 Financial Results
EQS-News: ABIVAX / Key word(s): Quarter Results Abivax Presents First Quarter 2025 Financial Results 02.06.2025 / 22:00 CET/CEST The issuer is solely responsible for the ...
29.04.25 - EQS
EQS-News: Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis
EQS-News: ABIVAX / Key word(s): Study Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis ...

Newssuche

Videos

newspaper
10:20 Uhr +1,73%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »